‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Summary
Regulatory authorities and multiple state governments are seeking contempt charges against Martin Shkreli. The legal action stems from allegations that he improperly influenced the stock prices of biopharmaceutical companies.
The Federal Trade Commission and seven states say Shkreli should be held in contempt
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.